Systemic release of high mobility group box 1 (HMGB1) protein is associated with severe and fatal Plasmodium falciparum malaria

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Higgins, Sarah J ^a,b   Xing, Katharine ^a   Kim, Hani ^a   Kain, Dylan C ^a   Wang, Feng ^a   Dhabangi, Aggrey ^c   Musoke, Charles ^c   Cserti Gazdewich, Christine M ^a   Tracey, Kevin J ^d   Kain, Kevin C ^a,b   Liles, W Conrad ^a,b,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAKERERE UNIVERSITY   (Uganda)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarker; HMGB1; Inflammation; Pathogenesis; Severe malaria

Indexed keywords

BIOLOGICAL MARKER; HIGH MOBILITY GROUP PROTEIN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FATALITY; FEMALE; IN VITRO STUDY; MALARIA FALCIPARUM; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN SECRETION; RAT; RECEIVER OPERATING CHARACTERISTIC;

ANIMALS; ANTIBODIES, NEUTRALIZING; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALARIA; MALARIA, FALCIPARUM; MALE; MICE; MICE, INBRED C57BL; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME; UGANDA;

EID: 84875071681     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-105     Document Type: Article

References (21)

1. WHO, World Malaria Report: Disease burden and trends Geneva: World Health Organization 2010
2. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ, AQUAMAT group, Lancet 2010 376 1647 1657 10.1016/S0140-6736(10)61924-1 21062666
3. Changes in the burden of malaria in sub-Saharan Africa. O'Meara WP, Mangeni JN, Steketee R, Greenwood B, Lancet Infect Dis 2010 10 545 555 10.1016/S1473-3099(10)70096-7 20637696
4. Human malarial disease: a consequence of inflammatory cytokine release. Clark IA, Budd AC, Alleva LM, Cowden WB, Malar J 2006 5 85 10.1186/1475-2875-5- 85 17029647 (Pubitemid 44687371)
5. HMGB1 is a therapeutic target for sterile inflammation and infection. Andersson U, Tracey KJ, Annu Rev Immunol 2011 29 139 162 10.1146/annurev- immunol-030409-101323 21219181
6. HMG-1 as a late mediator of endotoxin lethality in mice. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ, Science 1999 285 248 251 10.1126/science.285. 5425.248 10398600 (Pubitemid 29329996)
7. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ, Proc Natl Acad Sci USA 2004 101 296 301 10.1073/pnas.2434651100 14695889 (Pubitemid 38084244)
8. Role of HMGB1 in apoptosis-mediated sepsis lethality. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H, J Exp Med 2006 203 1637 1642 10.1084/jem.20052203 16818669 (Pubitemid 44036267)
9. Combined measurement of soluble and cellular ICAM-1 among children with Plasmodium falciparum malaria in Uganda. Cserti-Gazdewich CM, Dzik WH, Erdman L, Ssewanyana I, Dhabangi A, Musoke C, Kain KC, Malar J 2010 9 233 10.1186/1475-2875-9-233 20712868
10. Cytoadherence in paediatric malaria: ABO blood group, CD36, and ICAM1 expression and severe Plasmodium falciparum infection. Cserti-Gazdewich CM, Dhabangi A, Musoke C, Ssewanyana I, Ddungu H, Nakiboneka-Ssenabulya D, Nabukeera-Barungi N, Mpimbaza A, Dzik WH, Br J Haematol 2012 159 223 236 10.1111/bjh.12014 22909232
11. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluste, Trans R Soc Trop Med Hyg 2000 94 Suppl 1 1 S90 11103309
12. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH, Vassalli P, Science 1987 237 1210 1212 10.1126/science.3306918 3306918 (Pubitemid 17124914)
13. Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. Engwerda CR, Mynott TL, Sawhney S, De Souza JB, Bickle QD, Kaye PM, J Exp Med 2002 195 1371 1377 10.1084/jem.20020128 12021316 (Pubitemid 34564338)
14. Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malaria. Amante FH, Haque A, Stanley AC, Rivera F, de L, Randall LM, Wilson YA, Yeo G, Pieper C, Crabb BS, de Koning-Ward TF, Lundie RJ, Good MF, Pinzon-Charry A, Pearson MS, Duke MG, McManus DP, Loukas A, Hill GR, Engwerda CR, J Immunol 2010 185 3632 3642 10.4049/jimmunol.1000944 20720206
15. CD8+ T cells and IFN-gamma mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. Claser C, Malleret B, Gun SY, Wong AY, Chang ZW, Teo P, See PC, Howland SW, Ginhoux F, Renia L, PLoS One 2011 6 18720 10.1371/journal.pone.0018720 21494565
16. IFN-gamma-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain. Villegas-Mendez A, Greig R, Shaw TN, de Souza JB, Gwyer Findlay E, Stumhofer JS, Hafalla JC, Blount DG, Hunter CA, Riley EM, Couper KN, J Immunol 2012 189 968 979 10.4049/jimmunol. 1200688 22723523
17. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ, Proc Natl Acad Sci USA 2010 107 11942 11947 10.1073/pnas.1003893107 20547845
18. High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria. Alleva LM, Yang H, Tracey KJ, Clark IA, Trans R Soc Trop Med Hyg 2005 99 171 174 10.1016/j.trstmh.2004.06.008 15653118 (Pubitemid 40104015)
19. Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study. Erdman LK, Dhabangi A, Musoke C, Conroy AL, Hawkes M, Higgins S, Rajwans N, Wolofsky KT, Streiner DL, Liles WC, Cserti-Gazdewich CM, Kain KC, PLoS One 2011 6 17440 10.1371/journal.pone.0017440 21364762
20. Murine cerebral malaria development is independent of toll-like receptor signaling. Togbe D, Schofield L, Grau GE, Schnyder B, Boissay V, Charron S, Rose S, Beutler B, Quesniaux VF, Ryffel B, Am J Pathol 2007 170 1640 1648 10.2353/ajpath.2007.060889 17456769 (Pubitemid 47339308)
21. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S, J Immunol 1999 162 3749 3752 10201887 (Pubitemid 29314747)